Status:

ACTIVE_NOT_RECRUITING

Theory-based Health Behaviour Change Intervention in Patients of Metabolic Syndrome With Chronic Kidney Disease

Lead Sponsor:

Chinese University of Hong Kong

Conditions:

Chronic Kidney Diseases

Metabolic Syndrome

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

The pilot study will adopt a 2-arm, pretest-posttest, and assessor-blind randomized controlled trial design to examine the feasibility and acceptability of a theory-based health behaviour change inter...

Detailed Description

Metabolic syndrome (MetS) is a worldwide chronic disease mainly due to unhealthy diets and sedentary lifestyles. According to the International Diabetes Federation (IDF) definition of MetS, patients m...

Eligibility Criteria

Inclusion

  • Participants are 18 years old and above;
  • Participants have both diagnoses of MetS based on IDF clinical diagnostic criteria (WC for Chinese: ≥ 90 cm in men and ≥ 80 cm in women, and fulfils two items of the following: TG ≥ 1.7 mmol/L or treatment for hypertriglycerides, HDL-C\<1.03 mmol/L in men or \<1.29 mmol/L in women or treatment for low HDL-C, FG ≥5.6 mmol/L or previously diagnosed type 2 diabetes, and BP ≥ 130/85 mmHg or treatment for hypertension). and CKD (eGFR \< 60 mL/min/1.73 m2 or a UACR ≥ 30 mg/g for at least three months);
  • No medical contraindications to exercise, including walking;
  • Participants are capable of understanding and providing informed consent;
  • Own a smartphone for accessing WeChat;
  • Being able to communicate in Chinese;
  • Stay in Chengdu during the study period.

Exclusion

  • Participants who cannot perform brisk walking exercise;
  • Participants who have already started dialysis or kidney transplant;
  • Current participation in another clinical trial related to health behaviour change or medical trial;
  • Participants who have doctor-diagnosed psychiatric illness;
  • Participants who have a cognitive impairment, which will be screened by the abbreviated mental test with a score lower than seven;
  • Adjustment of medication within half a year;
  • Participants who have performed regular planned exercise (Defined as at least 150 minutes of moderate-intensity aerobic activity or 75 minutes of high-intensity aerobic activity per week, or a combination of moderate-intensity and high-intensity aerobic activity) within the past month.

Key Trial Info

Start Date :

July 31 2024

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

May 30 2026

Estimated Enrollment :

40 Patients enrolled

Trial Details

Trial ID

NCT06527768

Start Date

July 31 2024

End Date

May 30 2026

Last Update

December 2 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

West China Hospital of Sichuan University

Chengdu, Sichuan, China, 610000